Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MITF | O75030 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | FBP1 | P09467 | 2/20 | 0.33 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.31 |
| ▸ | VCP | P55072 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13105362 | 0.81 | — | — | |
| SCHEMBL2890201 | 0.81 | MITF (0.46) | MITFALDH1A1MAPTHSP90AA1HTT | |
| SCHEMBL9041209 | 0.81 | MITF (0.46) | MITFALDH1A1MAPTHSP90AA1HTT | |
| SCHEMBL10808510 | 0.74 | CYP2C19 (0.38) | ALDH1A1HTTMEN1KMT2A | |
| SCHEMBL9475147 | 0.73 | ADRB1 (0.30) | — | |
| SCHEMBL10807957 | 0.69 | — | — | |
| SCHEMBL29418137 | 0.69 | FBP1 (0.44) | ALDH1A1MAPTHSP90AA1SMN1; SMN2MEN1 | |
| SCHEMBL29418089 | 0.69 | FBP1 (0.44) | ALDH1A1MAPTHSP90AA1SMN1; SMN2MEN1 | |
| SCHEMBL4400521 | 0.67 | FBP1 (0.37) | MITFALDH1A1MAPTHSP90AA1HTT | |
| SCHEMBL2701677 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212101-A1 | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | SMITHKLINE BEECHAM S.P.A. (IT) | 2003-11-13 | — | — | US | claimed |
| EP-1131295-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | Smithkline Beecham S.p.A. (IT) | 2001-09-12 | — | — | EP | claimed |
| WO-2000031037-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM S.P.A. (IT) | 2000-06-02 | — | — | WO | claimed |
| US-6780875-B2 | RESPIRATORY SYSTEM DISORDERS; ANTIINFLAMMATORY AGENTS; PSYCHOLOGICAL DISORDERS | SMITHKLINE BEECHAM S.P.A. (IT) | 2004-08-24 | — | — | US | disclosed |
| US-20030212101-A1 | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | SMITHKLINE BEECHAM S.P.A. (IT) | 2003-11-13 | — | — | US | disclosed |
| EP-1131295-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | Smithkline Beecham S.p.A. (IT) | 2001-09-12 | — | — | EP | disclosed |
| WO-2000031037-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM S.P.A. (IT) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212101-A1 | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | KCNH2, KCNA6, KCNA3 | MITF 3927/4885ALDH1A1 2589/4885MAPT 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.